Axel Hoos

Axel Hoos is an accomplished leader in the oncology and immuno-oncology sectors, currently serving as Chief Executive Officer at Scorpion Therapeutics since July 2021 and as a Director on the Board of Directors at NextPoint Therapeutics, Inc. since March 2023. With extensive experience at GSK from 2012 to the present, including roles as Senior Vice President and R&D Governance Chair for Oncology, Axel Hoos has significantly contributed to research and development in the field. Additionally, involvement with the Sabin Vaccine Institute and the Cancer Research Institute highlights commitment to advancing cancer therapies. Previous leadership roles include Directorships at TCR² Therapeutics and Imugene Limited, as well as a Global Medical Lead position at Bristol Myers Squibb. Axel Hoos holds an MD from Heidelberg University, a PhD from the DKFZ German Cancer Research Center, and completed a fellowship in cancer research at Memorial Sloan Kettering Cancer Center.